Skip to content

Reduction of Sweetened Beverages and Intrahepatic Fat

Effects of a Reduction of Sweetened Beverages Consumption in Overweight High Consumers on Cardiometabolic Risk Factors

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01394380
Acronym
REDUCS
Enrollment
29
Registered
2011-07-14
Start date
2011-10-31
Completion date
2014-04-30
Last updated
2014-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Metabolic Syndrome, Obesity

Keywords

sugar, sweetened beverages, hepatic steatosis, visceral obesity, metabolic syndrome

Brief summary

The study will enroll 68 overweight male and female subjects with a high (\> 2 3dl-can soda/day) consumption of sweetened beverage per day. After a run-in period of 4 weeks, subjects will be randomized to either a 12-week intervention arm in which sweetened beverages will be replaced by artificially sweetened, calorie-free beverages, or to a control arm. The following measurements will be performed at the end of the run-in period and at the end of the intervention period * intrahepatic fat concentration * visceral fat volume * changes in day-long metabolic profile from baseline(plasma glucose, insulin, and triglyceride concentrations) * changes in food intake and daily energy, carbohydrate and sugars intake from baseline

Interventions

OTHERartificially sweetened sodas

subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee

Sponsors

Centre Hospitalier Universitaire Vaudois
CollaboratorOTHER
Insel Gruppe AG, University Hospital Bern
CollaboratorOTHER
University of Lausanne
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* gender male or female * body mass index (BMI) \> 27 kg/m2 consumption of \> 2 3dl-can regular soda/day * low to moderate physical activity (\< 60 min walking/day; \< 3 exercise session/week

Exclusion criteria

* diabetes mellitus * liver, kidney or heart disease * any current drug treatment * contra-indications to MR examination (pacemaker, foreign bodies,etc) * pregnancy or planned pregnancy * active weight gain or weight loss (weight change \> 4 kg in the past 12 months) * consumption of drugs or illicit substances * consumption of more than 10g alcohol/day * vegetarians or subjects on special diets

Design outcomes

Primary

MeasureTime frameDescription
changes in intrahepatic fat concentrationat the end of run-in and after 12 weeks intervention/controlintrahepatic fat content measured by 1H-MRS

Secondary

MeasureTime frameDescription
changes in visceral fat volumeat the end of run-in and after 12 weeks of intervention/controlVisceral fat volume measured by MRI
changes in day-long metabolic profileat the end of run-in and after 12 weeks of intervention/controlPlasma glucose, insulin, non-esterified fatty acids, and triglycerides will be measured at 2-hourly intervals between 7:00 am and 5:00 pm. Participants will be fed standardized meals and either sweetened or artificially-sweetened beverages according to randomization
changes in food intake from baselineat the end of the run-in period and after 6, and 12 weeks of intervention/controlTotal energy intake, total carbohydrate intake, and total sugars intake will be evaluated by 3-day food record

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026